Metastatic Renal Cell Carcinoma Recruiting Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Metastatic Renal cell carcinoma

IndicationStatusPhase
DBCOND0030098 (Metastatic Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02330783Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsTreatment